开发一种用于筛选能够抑制结核分枝杆菌在人巨噬细胞中生长的新型化合物的细胞内筛选方法。
Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages.
作者信息
Sorrentino Flavia, Gonzalez del Rio Ruben, Zheng Xingji, Presa Matilla Jesus, Torres Gomez Pedro, Martinez Hoyos Maria, Perez Herran Maria Esther, Mendoza Losana Alfonso, Av-Gay Yossef
机构信息
Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Diseases of the Developing World, GSK, Tres Cantos, Madrid, Spain.
Diseases of the Developing World, GSK, Tres Cantos, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2015 Oct 26;60(1):640-5. doi: 10.1128/AAC.01920-15. Print 2016 Jan.
Abstract
Here we describe the development and validation of an intracellular high-throughput screening assay for finding new antituberculosis compounds active in human macrophages. The assay consists of a luciferase-based primary identification assay, followed by a green fluorescent protein-based secondary profiling assay. Standard tuberculosis drugs and 158 previously recognized active antimycobacterial compounds were used to evaluate assay robustness. Data show that the assay developed is a short and valuable tool for the discovery of new antimycobacterial compounds.
摘要
在此，我们描述了一种用于发现对人类巨噬细胞有活性的新型抗结核化合物的细胞内高通量筛选检测方法的开发与验证。该检测方法包括基于荧光素酶的初步鉴定检测，随后是基于绿色荧光蛋白的二次分析检测。使用标准抗结核药物和158种先前公认的活性抗分枝杆菌化合物来评估检测方法的稳健性。数据表明，所开发的检测方法是发现新型抗分枝杆菌化合物的一种简短且有价值的工具。
相似文献
1
Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages.
Antimicrob Agents Chemother. 2015 Oct 26;60(1):640-5. doi: 10.1128/AAC.01920-15. Print 2016 Jan.
2
Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Tuberculosis (Edinb). 2016 Mar;97:38-46. doi: 10.1016/j.tube.2015.12.003. Epub 2016 Jan 6.
3
Green fluorescent protein as a reporter in rapid screening of antituberculosis compounds in vitro and in macrophages.
Biochem Biophys Res Commun. 1998 Dec 18;253(2):431-6. doi: 10.1006/bbrc.1998.9147.
4
High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model.
Tuberculosis (Edinb). 2020 Sep;124:101958. doi: 10.1016/j.tube.2020.101958. Epub 2020 Jul 18.
5
Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
J Med Chem. 2018 Dec 27;61(24):11221-11249. doi: 10.1021/acs.jmedchem.8b01356. Epub 2018 Dec 13.
6
High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
Tuberculosis (Edinb). 2015 Dec;95(6):664-677. doi: 10.1016/j.tube.2015.06.003. Epub 2015 Jul 31.
7
Discovery of Mycobacterium tuberculosis α-1,4-glucan branching enzyme (GlgB) inhibitors by structure- and ligand-based virtual screening.
J Biol Chem. 2015 Jan 2;290(1):76-89. doi: 10.1074/jbc.M114.589200. Epub 2014 Nov 10.
8
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
ACS Infect Dis. 2017 Jun 9;3(6):428-437. doi: 10.1021/acsinfecdis.7b00006. Epub 2017 May 11.
9
Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages.
Biochem Biophys Res Commun. 2000 Dec 20;279(2):457-61. doi: 10.1006/bbrc.2000.3957.
10
Zanthoxylum capense constituents with antimycobacterial activity against Mycobacterium tuberculosis in vitro and ex vivo within human macrophages.
J Ethnopharmacol. 2013 Mar 7;146(1):417-22. doi: 10.1016/j.jep.2013.01.013. Epub 2013 Jan 18.
引用本文的文献
1
Description of bacterial RNA transcripts detected in - infected cells from peripheral human granulomas.
Virulence. 2025 Dec;16(1):2547326. doi: 10.1080/21505594.2025.2547326. Epub 2025 Aug 25.
2
infection model: a powerful high-throughput screening platform for anti-infective compounds.
Front Microbiol. 2025 Jul 4;16:1612354. doi: 10.3389/fmicb.2025.1612354. eCollection 2025.
3
Fragment-Based Development of Small Molecule Inhibitors Targeting Cholesterol Metabolism.
J Med Chem. 2025 Jul 24;68(14):14416-14441. doi: 10.1021/acs.jmedchem.5c00478. Epub 2025 Jul 13.
4
High-throughput screening of small molecules targeting in human iPSC macrophages.
Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0161324. doi: 10.1128/aac.01613-24. Epub 2025 May 27.
5
Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.
Drug Resist Updat. 2025 May;80:101213. doi: 10.1016/j.drup.2025.101213. Epub 2025 Feb 15.
6
Toward Virulence Inhibition: Beyond Cell Wall.
Microorganisms. 2024 Dec 26;13(1):21. doi: 10.3390/microorganisms13010021.
7
Fragment-based development of small molecule inhibitors targeting cholesterol metabolism.
bioRxiv. 2024 Dec 3:2024.10.28.620643. doi: 10.1101/2024.10.28.620643.
8
Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.
bioRxiv. 2024 Oct 10:2024.10.10.617558. doi: 10.1101/2024.10.10.617558.
9
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0035724. doi: 10.1128/aac.00357-24. Epub 2024 Sep 30.
10
Description of Bacterial RNA Transcripts Detected in - Infected Cells from Peripheral Human Granulomas using Single Cell RNA Sequencing.
bioRxiv. 2024 Aug 20:2024.08.20.608852. doi: 10.1101/2024.08.20.608852.
本文引用的文献
1
Mycobacterial genes essential for the pathogen's survival in the host.
Immunol Rev. 2015 Mar;264(1):319-26. doi: 10.1111/imr.12256.
2
Macrophage defense mechanisms against intracellular bacteria.
Immunol Rev. 2015 Mar;264(1):182-203. doi: 10.1111/imr.12266.
3
Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment.
PLoS Pathog. 2015 Feb 12;11(2):e1004679. doi: 10.1371/journal.ppat.1004679. eCollection 2015 Feb.
4
The tuberculosis drug discovery and development pipeline and emerging drug targets.
Cold Spring Harb Perspect Med. 2015 Jan 29;5(6):a021154. doi: 10.1101/cshperspect.a021154.
5
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2015 Jan;59(1):693-7. doi: 10.1128/AAC.03705-14. Epub 2014 Oct 27.
6
Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion.
Cell Host Microbe. 2014 Oct 8;16(4):538-48. doi: 10.1016/j.chom.2014.09.008.
7
Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth.
PLoS Pathog. 2014 Feb 20;10(2):e1003946. doi: 10.1371/journal.ppat.1003946. eCollection 2014 Feb.
8
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
J Vis Exp. 2014 Jan 17(83):e51114. doi: 10.3791/51114.
9
Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing.
Cell. 2013 Dec 5;155(6):1296-308. doi: 10.1016/j.cell.2013.10.045.
10
Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model.
Int J Antimicrob Agents. 2013 Dec;42(6):524-30. doi: 10.1016/j.ijantimicag.2013.07.014. Epub 2013 Sep 5.
Zotero 插件